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Summary carcinoma, and embryonal rhabdomyosarcoma). The
tumor predisposition is quite signiﬁcant relative to the
The Beckwith-Wiedemann syndrome (BWS) is marked baseline population but is moderate in absolute terms:
by fetal organ overgrowth and conveys a predisposition õ10% of affected individuals will develop a childhood
to certain childhood tumors, including Wilms tumor neoplasm (reviewed in Junien 1992; Mannens et al.
(WT). The genetics of BWS have implicated a gene that 1994; Weksberg and Squire 1996). BWS is often diag-
maps to chromosome 11p15 and is paternally im- nosed on the basis of the presence of variably prominent
printed, and the gene encoding the cyclin-cdk inhibitor ﬁndings of hemihypertrophy, macroglossia, omphalo-
p57KIP2 has been a strong candidate. By complete se- cele, and ear creases and pits, and this condition must be
quencing of the coding exons and intron/exon junctions, clinically distinguished from certain other overgrowth
we found a maternally transmitted coding mutation in syndromes (Weksberg and Squire 1996). A number of
the cdk-inhibitor domain of the KIP2 gene in one of ﬁve observations have suggested that the BWS gene(s) are
cases of BWS. The BWS mutation was an in-frame on chromosome 11 and that at least one of these genes
three-amino-acid deletion that signiﬁcantly reduced but is in band 11p15.5 and is subject to parental imprinting.
did not fully abrogate growth-suppressive activity in a Familial BWS shows linkage to chromosome 11p15
transfection assay. In contrast, no somatic coding muta- (Koufos et al. 1989; Ping et al. 1989), and there appears
tions in KIP2 were found in a set of 12 primary WTs to be an excess of maternal transmissions; some cases
enriched for cases that expressed KIP2 mRNA, including of BWS are associated with uniparental paternal disomy
cases with and without 11p15.5 loss of heterozygosity. of this chromosomal region, and a third class of cases
Two other 11p15.5 loci, the linked and oppositely im- are associated with chromosomal translocations with
printed H19 and IGF2 genes, have been previously im- breakpoints on chromosome 11p, sometimes although
plicated in WT pathogenesis, and several of the tumors not always localizing to 11p15.5 (Mannens et al. 1994).
with persistent KIP2 mRNA expression and absence of Some cases of BWS show pathological biallelic expres-
KIP2 coding mutations showed full inactivation of H19. sion of the maternally imprinted 11p15.5 gene IGF2 in
These data suggest that KIP2 is a BWS gene but that it is some tissues (Weksberg et al. 1993), and at least some
not uniquely equivalent to the 11p15.5 ‘‘WT2’’ tumor- such cases have shown abnormal biallelic CpG hyper-
suppressor locus. methylation of the closely linked and oppositely im-
printed H19 gene (Reik et al. 1995). Several cases have
also been described of a severe generalized overgrowthIntroduction
syndrome similar to BWS, with nephromegaly and a
The Beckwith-Wiedemann syndrome (BWS) is charac- predisposition to WT but without prominent macro-
terized by somatic overgrowth of various tissues, includ- glossia or omphalocele, in which the hypertrophied tis-
ing kidney, liver, adrenal and skeletal muscle, and by sues have shown biallelic hypermethylation of H19 and
a predisposition to embyronal tumors of these organs biallelic expression of IGF2 (Morison et al. 1996).
(Wilms tumor [WT], hepatoblastoma, adrenal cortical Imprinted genes on chromosome 11p15.5 are also im-
plicated in sporadic WTs: 45% of WTs show 11p15.5
loss of heterozygosity (LOH) because of mitotic recom-
bination, and invariably there is loss of the maternalReceived October 28, 1996; accepted for publication May 16, 1997.
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genes, which lead to a ‘‘bipaternal epigenotype.’’ These plications unrelated to BWS. Two other siblings were
normal. In all cases, other known overgrowth syn-tumors show complete inactivation of the paternally im-
printed H19 gene, with CpG hypermethylation of the dromes were judged to be unlikely, by clinical criteria;
for example, the X-linked Simpson-Golabi-Behmel syn-previously active maternal allele (Moulton et al. 1994;
Steenman et al. 1994; Taniguchi et al. 1995), and, since drome, which can also manifest some signs in females
(Weksberg and Squire 1996), was clinically ruled un-the H19 and IGF2 promoters compete for enhancer ele-
ments in cis (Leighton et al. 1995), the inactivation of likely, by the absence of skeletal abnormalities and
coarse facies. Standard karyotypes were obtained forH19 invariably correlates with a reciprocal activation
of the maternal allele of IGF2 in these tumors. The BWS1, BWS2, and BWS3, and all were 46,XX; a karyo-
type was not available for BWS4 and BWS5. BWS1,inactivation of H19 may contribute to WT formation
either via this cis effect on IGF2 expression, or via elimi- BWS2, BWS3, and BWS5 survived the perinatal period,
but BWS4 died perinatally and did not survive longnation of a trans growth–inhibiting effect of H19 RNA
(Hao et al. 1993), or via both mechanisms. enough for surgical correction of a severe omphalocele,
which contained portions of bowel, liver, and kidney.With regard to both BWS and WT, much recent atten-
tion has focused on the KIP2 gene. This gene encodes None of the BWS cases have shown clinical or pathologi-
cal evidence of neoplasms (BWS1 is 14 mo old, BWS2the cyclin-cdk inhibitor p57KIP2 (Matsuoka et al. 1995),
maps to chromosome 11p15.5 in the vicinity of some is 3 years old, BWS3 is 16 mo old, and BWS5 is 5 mo
old). Tumors and paired nonneoplastic kidney samplesalthough not all of the BWS translocation breakpoints
(Hoovers et al. 1995), and is paternally imprinted in were obtained from WT patients at surgery. All were
primary unilateral tumors with typical nonanaplasticmice and humans, albeit with variable ‘‘leaky’’ expres-
sion of the paternal allele in humans (Hatada and Mukai histologies. None of the WT patients showed clinical
evidence of BWS; only WT537 and WT540 were famil-1995; Chung et al. 1996; Hatada et al. 1996a; Kondo
et al. 1996; Matsuoka et al. 1996). A large subset of ial (Moulton et al. 1996).
WTs show transcriptional inactivation of KIP2 (Chung
KIP2 and H19 Expression and H19 CpG Methylationet al. 1996; Hatada et al. 1996a), but some cases, both
those with and those without 11p15.5 LOH, show per- KIP2 mRNA was quantitated by RNAse protection
assay (RPA), and H19 RNA was quantitated by north-sistent expression of this gene (Chung et al. 1996; Ha-
tada et al. 1996a; Overall et al. 1996). Here we describe ern blotting as described elsewhere (Chung et al. 1996).
As has been described elsewhere, KIP2 mRNA quantita-our sequence analysis of the complete coding region of
the KIP2 gene in several cases of BWS and in a large tions by northern analysis and RPA are highly concor-
dant (Chung et al. 1996). Allelic CpG methylation ofseries of WTs with characterized 11p15.5 allelic status
and KIP2 and H19 expression. H19 genomic DNA was assessed by digestion with
methylation-sensitive restriction enzymes and Southern
blotting, as described elsewhere (Moulton et al. 1994;Patients, Material, and Methods
Chung et al. 1996).
Patients and Tumors
Reverse-Transcription–PCR (RT-PCR) for KIP2 mRNAAll ﬁve index BWS cases were evaluated at the clinical
genetics service of Babies Hospital, Columbia Univer- RT-PCR was done as described elsewhere (Chung et
al. 1996), except that the upstream primer was primersity. All were females. Cases BWS1, BWS2, and BWS4
were diagnosed on the basis of the presence of omphalo- 13, in the 5 end of exon 2, and the downstream primer
was primer 12, in the 3 end of exon 4 (primers arecele, macroglossia, and ear creases and pits. The ompha-
loceles in BWS1 and BWS2 required surgical correction, listed below). The PCR therefore spanned two introns;
nested primers was not required, since placenta ex-and the macroglossia in BWS2 also required surgical
correction by partial glossectomy. BWS2 also showed presses higher levels of KIP2 mRNA than is seen in most
other organs. The PCR products were digested withhemihypertrophy. BWS3 was a large infant, with a
birthweight and placental weight both ú90th percentile ApaI prior to sizing analysis, to better visualize the
BWS1 deletion.and with macroglossia, ear creases, and an umbilical
hernia, but there was no omphalocele or hemihypertro-
SSCP Analysisphy. BWS5 was diagnosed on the basis of omphalocele,
capillary hemangiomas over her eyelids bilateraly, and SSCP was performed with 32P-labeled PCR products
spanning the coding exons of KIP2, by means of a de-macroglossia. In this case there was also severe hypogly-
cemia after birth, which resolved during the postnatal scribed protocol elsewhere (Tycko et al. 1996) but with
electrophoresis at room temperature and with 400–500period. Only BWS1 had a positive family history: A
sister of the proband had macroglossia and severe om- V. This was found to improve the quality of band pat-
terns with the C/G-rich KIP2 sequences. Where neces-phalocele and died, during the perinatal period, of com-
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sary, the labeled PCR products were digested with re- plates, by use of LipofectinTM (Gibco-BRL Life Technol-
ogies) according to the manufacturer’s instructions. Instriction enzymes prior to SSCP, to reduce the fragment
sizes to õ350 bp. brief, the indicated plasmids (4 or 8 mg) were incubated
with 40 ml of Lipofectin prior to transfection. Cells were
PCR Primers and Genomic Sequencing incubated with the Lipofectin-DNA complexes in se-
rum-free media overnight, after which time the mediumThe PCR sequencing strategy for analysis of the KIP2
was replaced with the cells’ usual medium. After 48 h,gene is shown in ﬁgure 1. The primers used for PCR
the cells were selected in maintenance medium con-were pairs 1/3, 2/6, 4/8, 7/9, 10/11, and 10/12.
taining 600 mg/ml Geneticin (Sigma). After 15 d in selec-Each primer except primer 1 was also used for direct
tion, the plates were washed and ﬁxed in 5% formalinsequencing, and primer 5 was used for additional se-
in PBS and were stained with Giemsa. Colonies werequencing of the 4/8 PCR product. Since the 4/8 prod-
counted within a 10-cm2 standard grid applied to eachuct includes the insertion/deletion polymorphism, plas-
plate.mid cloning and sequencing of six clones per sample
was also performed for this PCR product. Primer se-
quences were as follows: 1, CTACATTATGCTAAT- Results
CGCGG; 2, TCTTCTCGCTGTCCTCTCCT; 3, AGG-
The entire KIP2 coding region and splice-donor andAGAGGACAGCGAGAAGA; 4, CCGAAGTGGACA-
-acceptor signals were examined in 5 individuals withGCGACTCG; 5, CGGTCGCGGTGGCTGTCA; 6,
clinical BWS and in a set of 12 WTs enriched for casesCGCCCCACCTGCACCGTCT; 7, TCAAGAGAG-
that expressed KIP2 mRNA. The clinical characteristicsCGCCGAGCAG; 8, CTGGTCAGCGAGAGGCTCCT;
of the BWS cases are listed above (see Patients, Material,9, GCGGGCCCTTTAATGCCAC; 10, TCTCCCGGC-
and Methods section). Of the ﬁve cases, one, BWS1,CCCCTCTCGG; 11, TCAGCAAAGCCGGCGGGGA;
showed aKIP2 coding-region mutation. This was a dele-12, CAAAACCGAACGCTGCTCTG; and 13, CCT-
tion of nine nucleotides, leading to a predicted deletionTCCCAGTACTAGTGCGC.
of three amino acids, as well as a change of one amino
acid, in the cdk-inhibitor domain of the protein (tableColony-Suppression Assay
1 and ﬁg. 2A). This deletion, which interrupts a sequenceOligonucleotide primers were designed to amplify the
that is colinear and well conserved in the murine Kip2major mRNA species of KIP2 (Tokino et al. 1996) incor-
gene, was not observed in any of 105 unaffected individ-porating artiﬁcialEcoRI and SalI restriction sites (under-
uals (210 chromosomes). That the deletion was presentlined) (5 primer CAGGAATTCCACGATGGAGCGTC
on the active (nonimprinted) allele of the affected childand 3 primer GGGCTGTCGACTGGCTCACCG, re-
was conﬁrmed by RT-PCR analysis of cDNAs from thespectively). Normal KIP2 cDNA and the BWS1 KIP2
placenta (ﬁg. 2B). As for the other members of the fam-cDNA deletion constructs were generated by RT-PCR
ily, the germ-line deletion was present in the mother andof normal placental RNA and BWS1 placental RNA,
the affected child from whom DNA was available andrespectively. The resulting products were cloned in the
was absent in the father and an unaffected child (ﬁg.EcoRI and SalI sites of pBluescript KS and subsequently
2B). Three siblings of the mother, as well as the maternalwere subcloned into the KpnI/SacI sites of pBKCMV
grandfather, were also examined, but none carry the(Stratagene). SAOS-2 cells were maintained in Iscove’s
mutated KIP2 allele (data not shown). None of the othermodiﬁed Dulbecco’s medium containing 10% FCS at
four BWS probands showed KIP2 coding or splice-site37C in 5% CO2. Transfections were performed when
mutations, and a bipaternal genotype via uniparentalthe cells were at 40% conﬂuency in 10-cm-diameter
disomy for chromosome 11p15.5 was also excluded for
each of these cases, by genotyping with a series of highly
polymorphic chromosome 11p15.5 markers (data not
shown).
To determine whether the KIP2 allele with the three-
amino-acid deletion present in BWS1 was functionally
altered, we cloned it and the normal cDNA encoding the
major transcript of KIP2 into the pBKCMV expression
Figure 1 Sequencing strategy for the KIP2 gene. The PCR se- vector and introduced the constructs into SAOS-2 cells.
quencing primers are indicated by arrows; the coding region is denoted Elsewhere, these cells have been shown to respond to
by gray shading; the PAPV-repeat deletion/insertion polymorphism is overexpression of p57KIP2 in transient-transfection
denoted by the blackened solid box; and the GC-rich repeat is denoted
assays, by accumulating in the G1 phase of the cell cycleby hatching. Direct sequencing was used for all of the regions, and
(Matsuoka et al. 1995). We used a stable transfectionthis was supplemented by plasmid sequencing for the polymorphic
region between primers 4 and 8. assay to determine the ability of the BWS1 deletion allele
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Table 1
p57/KIP2 Sequence Analysis of WTs and BWS, and Comparison of KIP2 and H19 RNA Expression in WTs
Status of H19 CpG
Casea 11p15 Alleles Methylationb H19 RNAc KIP2 RNAc KIP2 Polymorphism(s)d KIP2 Mutation
WT251 LOH /// õ.05 .18 3, 5, 7 None
WT540 LOH /// õ.05 .40 1, 2, 3, 4 None
WT802 LOH /// õ.05 .22 3, 4 None
WT667 LOH /// õ.05 .11 4, 5, 6, 8 None
WT753 LOH /// õ.05 .20 3, 4 None
WT616 LOH /// õ.05 .06
WT521 LOH /// ND õ.05
WT903 LOH /// õ.05 õ.05
WT428 ROH /// õ.05 õ.05
WT511 ROH /// õ.05 õ.05
WT515 ROH /// õ.05 .07
WT516 ROH /// õ.05 .25 3, 4 None
WT517 ROH /// õ.05 õ.05
WT899 ROH /// õ.05 õ.05
WT931 ROH /// õ.05 .19 1, 3, 4 None
WT537 ROH //0 ú1 .45 None
WT564 ROH //0 ú1 .61 3, 4 None
WT650 ROH //0 ú1 .05 4, 5 None
WT914 ROH //0 .80 .42 3 None
WT933 ROH //0 ú1 õ.05 3 None
BWS 1 NA NA NA NA Deletion of 9 nt (445–453 cDNA)
BWS 2 NA NA NA NA None
BWS 3 NA NA NA NA None
BWS 4 NA NA NA NA 3, 9 None
BWS 5 NA NA NA NA None
NONE.—NA Å not applicable; and ND Å not done.
a The entire series of WTs is shown, to illustrate the lack of a strict correlation between H19 and KIP2 expression and the selection to enrich
for KIP2-expressing cases for sequencing. Cases selected for sequencing are underlined.
b /// Å Biallelic DNA hypermethylation; and //0 Å monoallelic hypermethylation.
c RNA expression is relative to that of whole fetal kidney.
d Referenced to nucleotide positions in the genomic and DNA sequences (GenBank D64137 and U22398). 1 Å TrC (839 cDNA); 2 Å TrC
(667 cDNA); 3 Å CrT (815 cDNA); 4 Å four-amino-acid PAPV-repeat deletion/insertion (del760–771 cDNA); 5 Å insertion of G (2774
genomic, third intron); 6 Å CTrTC (772–773 cDNA); 7 Å TrC (725 cDNA); 8 Å GrA (866 cDNA); and 9 Å CrT (1053 genomic,
5 UTR). All of the single-nucleotide polymorphisms except 6 are neutral with respect to the amino acid sequence; polymorphism 6 is a
conservative alarval change within the PAPV repeat. In addition, all samples showed both a C instead of a G at position 2079 and an insertion
of a G after C2600 of the genomic sequence; both of these changes are in the second intron and may reﬂect either errors in the GenBank
sequence or rare sequence polymorphisms in the population.
to confer colony suppression. The results indicated a tween other Kip/Cip family members, p27KIP1and
p21Cip1. By analogy with the crystal structure determinedreproducible partial loss of biological activity of this
allele. Speciﬁcally, the ability of p57KIP2 to suppress colo- for p27KIP1, the DYDF sequence is predicted to form
part of a beta-hairpin structure in a region responsiblenies was almost although not entirely abrogated by the
9-bp deletion (table 2), and there were also differences for binding to and inducing structural changes in Cdk2
(Russo et al. 1996).between the morphology of the colonies generated by
the two constructs and that of the vector-alone control Although none of the cases of BWS in our series has
developed a neoplasm, at least a subset of individuals(ﬁg. 3). The KIP2 deletion allele generated colonies that
were somewhat smaller than those generated by vector with the clinical syndrome of BWS are predisposed to
the development of WT. Elsewhere we have character-alone, but the wild-type KIP2 control had far fewer
colonies, and these were very small (õ20 cells) and con- ized a series of tumors including 19 histologically typical
and nonpretreated WTs for H19 and KIP2 expressionsisted of ﬂat cells that did not pile up (table 2 and ﬁg.
3). That the deletion in theKIP2 allele impairs biological (Chung et al. 1996). From this series, supplemented by
two additional cases, we chose 10 WTs with persistentactivity is not suprising, since the deleted DYDF motif
is conserved (with the same or similar amino acids) be- KIP2 mRNA, deﬁned as ú10% of whole fetal kidney
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was that a minor class of coding-region mutation or
splice-site mutation can, in principal, destabilize the
mRNA and lead to an apparent lack of expression.
Sequencing revealed nine neutral or conservative se-
quence polymorphisms in KIP2 exons and introns, in-
cluding the previously identiﬁed PAPV-repeat length
polymorphism in exon 2 (Orlow et al. 1996; Tokino et
al. 1996) but also including several novel polymor-
phisms, as well as, within the second intron, two uni-
form discrepancies with the GenBank sequence. None
of theWTs containedKIP2 coding or splice-signal muta-
tions (table 1). The SSCP analyses were consistent with
the sequence data, since they showed a pattern of bands
that was polymorphic from case to case but that did
not show evidence of variability within normal/tumor
pairs—that is, somatic mutations (ﬁg. 4 and data not
shown). On the basis of the combined expression and
sequence data, we conclude that, although KIP2 is deﬁ-
nitely transcriptionally repressed in a large subset of
WTs, somatic coding mutations in this gene are rare
in tumors with persistent KIP2 mRNA expression, as
indicated by their complete absence in our series. WeFigure 2 Germ-line KIP2 coding mutation in a family with
wish to emphasize that in this study we have not ex-BWS. A, Plasmid sequencing of the mutated allele in proband BWS1.
There is in exon 2 a 9-nucleotide deletion that deletes three amino cluded the possibility of regulatory mutations in pro-
acids and changes the identity of one amino acid in the CDK-inhibitor moter/enhancer elements of the KIP2 gene in cases of
domain. The inset shows RsaI fragments of genomic PCR with primers WT that lack KIP2 expression.
2/6, revealing the deletion in the affected child (1) and the mother
The rarity ofKIP2 coding mutations in sporadic WTs,(2) and its absence in three unrelated individuals (a total of 40 controls
together with the previous ﬁndings of dysregulated ex-lacked the deletion). M Å size markers (in bp). B, Occurrence of the
deletion on the active (nonimprinted) maternal allele. The left-hand pression of both this gene and other 11p15.5 imprinted
panel shows RT-PCR products (cDNA) from the region of KIP2 exon genes in these tumors, favors the hypothesis that the
2 containing the deletion. The lower (i.e., deletion) band is present in 11p15.5 ‘‘WT2’’ tumor-suppressor locus may in fact
the placental (Pl) cDNA from BWS1 but not in the placental cDNA
consist of multiple genes. Also consistent with this is thefrom BWS3 or in control (C) placenta and kidney (Ki). BWS1 also
shows a faint upper band representing leaky expression from the im-
printed allele; this was seen more clearly on radiolabeling (not shown).
The RT-PCR products were digested with ApaI prior to electrophore-
sis; only the smaller (i.e., 5) fragments, containing the deleted region, Table 2
are shown. The right-hand panel shows genomic PCR products (G)
from the mother (M), from BWS1, from the father (F), and from an Functional Analysis of the p57/KIP2 Deletion Allele,
unaffected sibling (S). The size markers that apply to the left-hand by a Colony-Suppression Assay in Saos-2 Cells
panel do not apply to this panel; the genomic PCR fragments are
slightly larger, as indicated in A. NO. OF COLONIES COUNTED IN 102-
cm GRID
Experiment 1: Experiment 2:
levels, as well as 2 WTs that showed very low or unde- 5 mg Plasmid/ 8 mg Plasmid/
tectable KIP2 expression by RPA, for SSCP analysis and Plate Plate
complete genomic sequencing of the KIP2 coding region
Plate 1 Plate 2 Plate 1 Plate 2and intron-exon boundaries. Consistent with the ‘‘leaki-
ness’’ of the KIP2 paternal imprint (Chung et al. 1996;
Vector alone 273 374 512 547
Kondo et al. 1996; Matsuoka et al. 1996), ﬁve of the BWS1 deletion KIP2 cDNA 288 202 494 464
expressing tumors showed 11p15.5 LOH; this ﬁnding Normal KIP2 cDNA 130 151 289 250
of persistent KIP2 mRNA in WTs with 11p15.5 LOH
NOTE.—A third plate was used for preparation of genomic DNA,has also been described in another study (Overall et al.
and duplicate slot blots of genomic DNA from parallel plates of cells1996). Our rationale for enriching for expressing cases
after selection were hybridized with a vector-derived (CMV-promoter)
was that most coding-region mutations would be ex- probe and a total-human-DNA probe. The results indicated that the
pected to have functional signiﬁcance in such cases; our amount of plasmid stably transfected was equal for each of the three
constructs in a given experiment (data not shown).rationale for also including two nonexpressing tumors
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Figure 3 Morphology of p57KIP2 Saos-2 transfectants. A, Typical colony obtained with the control CMV/neo vector. B, Typical colony
obtained with the BWS1 p57KIP2 deletion construct. C, Typical colony obtained with the normal wild-type p57KIP2 construct. In addition to
the reduction in colony numbers, the colonies that formed contained fewer and ﬂatter cells, compared with those obtained with the vector
control and BWS1 deletion constructs. D, Isolated nonproliferating cells seen with the normal p57KIP2 construct after 2 wk of selection. These
were not seen in the vector control or BWS1 deletion construct plates.
lack of an absolute correlation between transcriptional BWS, the presence of a germ-line mutation in the KIP2
gene in one of ﬁve affected children suggests that KIP2inactivation of H19 and KIP2 in our series of WTs. In
our expanded series, among seven WTs with ROH and is a BWS gene. The paternal imprinting of this gene
(Hatada and Mukai 1995; Chung et al. 1996; Hatadabiallelic hypermethylation and complete (õ.05 vs. fetal
kidney) inactivation of H19, ﬁve showed very low KIP2 et al. 1996a; Kondo et al. 1996; Matsuoka et al. 1996),
the tissue distribution of its expression, and the pre-expression, but two showed easily detectable KIP2
dicted growth-inhibiting effects of its product (Matsu-mRNA at Ç20% of the fetal kidney level; conversely,
oka et al. 1995) are all consistent with this. However,among ﬁve WTs with persistent high H19 expression,
since most of our BWS cases lacked coding mutations,three also showed high KIP2 mRNA levels, whereas two
our data suggest that KIP2 is not the only gene in-showed complete inactivation of KIP2 (table 1). This
volved in this syndrome. Our data are concordant withlack of an absolute correlation between the inactivation
a previous report from Hatada et al. (1996b), whichof KIP2 and H19 is consistent with these two loci being
described KIP2 germ-line mutations in two of ninephysically linked but, at least in some cases, functionally
BWS cases. Interestingly, of the two mutations in thatindependent targets of inactivation. Also consistent with
study, one was a frameshift resulting in disruption ofthis, DNA methylation may play a more important role
the QT domain, which would leave the cyclin/cdkin the functional imprinting of H19, compared with that
binding and inhibitory region of the protein intactof human KIP2 (Chung et al. 1996). Thus, the mecha-
(Matsuoka et al. 1995). These reports combined sug-nisms of inactivation of these two genes in WTs may
gest that Ç20%, or perhaps even a lesser percentage,not be identical.
of BWS cases are attributable to coding mutations in
KIP2 and that these mutations may tend to preserveDiscussion
partial biological activity of p57KIP2 protein. We specu-
These ﬁndings have implications for the genetic basis late that complete abrogation of p57KIP2-protein func-
of BWS and for the role of KIP2 and other imprinted tion may not be compatible with full-term fetal sur-
vival and that either (a) there may be selection forchromosome 11p15.5 genes in WTs. With regard to
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expressing WTs in our series showed amounts of KIP2
mRNA that were moderately reduced compared with
those in whole 16–23-wk fetal kidney levels. This most
likely reﬂects a real but moderate transcriptional down-
regulation, but, alternatively, since published in situ hy-
bridization data suggest that Kip2 is most highly ex-
pressed in differentiating condensed or tubular struc-
tures, as opposed to proliferating blastema, in the mouse
fetal kidney (Matsuoka et al. 1995), in some cases it
might reﬂect appropriately low expression due to the
early stage of cell differentiation in the blastemal compo-
nent of these tumors.
In addition to KIP2, other imprinted chromosome
11p15.5 genes are transcriptionally dysregulated inFigure 4 Representative KIP2 SSCP analyses in BWS and WTs.
WTs. Inactivation of H19, which occurs in 70% ofThe region of KIP2 exon 2 containing the PAPV length polymorphism
WTs, could promote tumorigenesis by loss of H19and several neutral single base polymorphisms was ampliﬁed with
primers 4/8, internally radiolabeled, and digested with PvuII to yield RNA (Hao et al. 1993) and/or by cis-activation of the
fragments of 320 and 164 bp. The left-hand panel shows the resulting linked and reciprocally imprinted IGF2 gene (Rainier
SSCP band patterns for both fragments (upper and lower vertical et al. 1993; Moulton et al. 1994; Steenman et al. 1994;brackets), and the right-hand panel shows the results for the larger
Taniguchi et al. 1995). In our series, seven of the KIP2-fragment only, after electrophoresis at a higher voltage. Although
expressing WTs that lacked coding mutations showedbands vary between individuals, comparisons of normal (N) and tu-
mor (T) lanes show no evidence of somatic mutations. LOH for the complete loss of H19 expression. Moreover, the inacti-
length polymorphism is seen in some of the tumor/normal pairs; in vation of H19 in WTs is clearly not related to the stage
every case this was consistent with LOH at other 11p15.5 markers. of cellular differentiation in these tumors (Moulton et
al. 1994) and is manifested as a pathological pattern
of biallelic DNA hypermethylation in this gene, a situa-
tion that has not been encountered in numerous con-nontruncating mutations with residual activity or (b)
in cases with more severe mutations, survival may de- trol non-neoplastic kidney tissues from fetuses and
adults outside the setting of WT or somatic-over-pend on leaky expression from the nonmutated im-
printed allele (Chung et al. 1996). growth syndromes (Moulton et al. 1994; Steenman et
al. 1994; Reik et al. 1995; Taniguchi et al. 1995; Mor-The ‘‘nonmutation’’ cases of BWS might still be
caused by down-modulation of KIP2 expression, via rison et al. 1996; Moulton et al. 1996). Since, in the
large subset of WTs with 11p15.5 ROH, there is nouniparental paternal disomy (Henry et al. 1991, 1993),
or perhaps by other imprinting aberrations, but it re- absolute correlation between KIP2 down-modulation
and H19 inactivation, we suggest that H19 and KIP2mains possible that genetic or epigenetic lesions in other
imprinted 11p15.5 genes with growth-regulating activ- are independently involved, via epigenetic inactiva-
tion, as WT-suppressor genes. In cases with 11p15.5ity might underlie these cases. Uniparental disomy was
not present in any of our BWS cases, and, in one of our LOH both of these imprinted genes are down-modu-
lated by a single ‘‘hit’’—mitotic recombination,nonmutation cases (BWS3) in which we were able to
examine RNA of the hypertrophied placenta, northern whereas in the non-LOH cases the tumor-precursor
cells may be under selective pressure to epigeneticallyblots showed abundant KIP2 mRNA with a normal
transcript size (data not shown). The extent to which target both loci for inactivation.
Although BWS conveys a marked predisposition toBWS is a genetically heterogeneous disorder should be-
come evident with further study. WT, relative to the risk in the general population, the
absolute percentage of BWS affecteds who develop tu-With regard to 11p15.5 genes and WT, the question
arises whether the identiﬁcation of KIP2 as a BWS gene mors is small, and no neoplasms have developed in the
cases in our series. Data from a limited number ofalso identiﬁes it as the sole or primary 11p15 tumor-
suppressor gene in WTs—that is, as the WT2 locus. cases have suggested that, among persons with BWS,
the predisposition to WT might be highest in thoseKIP2 expression is clearly signiﬁcantly down-modulated
in a majority of WTs, but the lack of somatic mutations who have uniparental paternal disomy for the entire
chromosome 11p15 region (Henry et al. 1993). If thisin this gene in expressing tumors, both in our series and
in other studies of WTs (studies in which the gene was is conﬁrmed in larger series, then the fact that these
individuals are predicted to have coordinate dysregula-subjected to partial sequenicing [Orlow et al. 1996;
Overall et al. 1996]), is a negative ﬁnding that argues tion of multiple imprinted 11p15 genes may be consis-
tent with the notion of WT2 as a multigene locus.against a unique assignment of KIP2 as WT2. All of the
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syndrome and a second Wilms tumor locus both map toFinally, since there is increasing evidence both for a
11p15.5. Am J Hum Genet 44:711–719domainlike clustering of imprinted genes and for the
Leighton PA, Ingram RS, Eggenschwiler J, Efstratiatis A,involvement of imprinted genes in cellular-growth con-
Tilghman SM (1995) Disruption of imprinting caused bytrol, chromosome 11p15 should continue to be ex-
deletion of the H19 gene region in mice. Nature 375:34–plored for additional imprinted genes involved in the
39
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